- Home
- FMY vs TPST Comparison
FMY vs TPST Comparison
Compare FMY & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- TPST
- Stock Information
- Founded
- FMY 2005
- TPST 2011
- Country
- FMY United States
- TPST United States
- Employees
- FMY N/A
- TPST N/A
- Industry
- FMY Finance/Investors Services
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- TPST Health Care
- Exchange
- FMY Nasdaq
- TPST Nasdaq
- Market Cap
- FMY 50.5M
- TPST 45.5M
- IPO Year
- FMY N/A
- TPST N/A
- Fundamental
- Price
- FMY $12.25
- TPST $9.58
- Analyst Decision
- FMY
- TPST Hold
- Analyst Count
- FMY 0
- TPST 3
- Target Price
- FMY N/A
- TPST $30.00
- AVG Volume (30 Days)
- FMY 10.1K
- TPST 54.6K
- Earning Date
- FMY 01-01-0001
- TPST 11-11-2025
- Dividend Yield
- FMY 6.98%
- TPST N/A
- EPS Growth
- FMY N/A
- TPST N/A
- EPS
- FMY N/A
- TPST N/A
- Revenue
- FMY N/A
- TPST N/A
- Revenue This Year
- FMY N/A
- TPST N/A
- Revenue Next Year
- FMY N/A
- TPST N/A
- P/E Ratio
- FMY N/A
- TPST N/A
- Revenue Growth
- FMY N/A
- TPST N/A
- 52 Week Low
- FMY $10.71
- TPST $5.35
- 52 Week High
- FMY $12.17
- TPST $20.67
- Technical
- Relative Strength Index (RSI)
- FMY 48.65
- TPST 47.99
- Support Level
- FMY $12.26
- TPST $9.90
- Resistance Level
- FMY $12.37
- TPST $11.02
- Average True Range (ATR)
- FMY 0.08
- TPST 0.62
- MACD
- FMY -0.00
- TPST -0.20
- Stochastic Oscillator
- FMY 39.13
- TPST 4.78
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.